A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."
The experimental shot is the most advanced candidate vaccine for malaria but results from...
GSK CEO Sir Andrew Witty and CFO Simon Dingemans on the group’s Q2 2014 results and strategy...
A recent Health Canada inspection of the country's only flu vaccine production plant identified...
GlaxoSmithKline and Theravance today announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).
Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.
A U.S. Embassy spokesman says diplomats are barred from the trial in Shanghai of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information. Spokesman Nolan Barkhouse said Friday that the U.S. government is concerned about lack of access to the trial of Yu Yingzeng and husband Peter Humphrey in August.
GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it marketed drugs for uses unapproved by federal regulators. Lawsuits filed in 44 states and the District of Columbia alleged that the British drugmaker misrepresented the uses and qualities of its asthma drug Advair and the antidepressants Paxil and Wellbutrin.
Britain's Serious Fraud Office says it has opened a criminal investigation into the commercial practices of GlaxoSmithKline PLC and its subsidiaries. The company has faced a series of investigations into its activities in recent months including a major corruption probe in China.
Pernix Therapeutics Holdings has signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet® (sumatriptan/naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.
Chinese police have accused a British executive of GlaxoSmithKline of leading a sprawling scheme to bribe doctors and hospitals to use its drugs. The announcement was the first time a foreign employee in China of British-based GSK was accused in the investigation announced last July.
Ligand Partner GSK Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic AnemiaApril 30, 2014 8:01 am | News | Comments
Ligand Pharmaceuticals has announced that the FDA has granted its partner GlaxoSmithKline Priority Review designation for Promacta™/Revolade™ (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.
Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.
GlaxoSmithKline and Genmab A/S announced that the FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate.
British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company said Wednesday that it started looking into the conduct of "a small number of individuals" in December. It says the investigation is ongoing.
The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The agency cleared the company's drug, Tanzeum, to help patients control their blood sugar levels, in combination with diet and exercise.
The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. A "Panorama" show to air Monday evening quotes a former sales representative for the company saying doctors there were paid to prescribe its drugs.
GlaxoSmithKline is recalling the weight loss drug Alli after receiving reports of unknown pills and tablets in the bottles.
Mylan has announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GSK relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.
Agenus Inc. announced that GlaxoSmithKline’s MAGRIT i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon ® adjuvant, did not meet its first or second co-primary endpoint.
New research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV.
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.
GlaxoSmithKline says fourth-quarter earnings nearly tripled and sales rose 5 percent, even as an ongoing investigation hurt business in China.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
Ligand Pharmaceuticals announced that its drug Promacta has received "breakthrough" designation by U.S. regulators for a new use in patients with a rare form of anemia. Ligand and its partner GlaxoSmithKline already market the pill to treat chronic hepatitis C and a rare condition called chronic immune thrombocytopenic purpura, in which the body attacks its own platelets.
The FDA has approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage). In May 2013, the FDA approved both drugs as single agents to treat patients with unresectable or metastatic melanoma.
- Page 1